Taylor-Robinson David C, Maayan Nicola, Soares-Weiser Karla, Donegan Sarah, Garner Paul
International Health Group, Liverpool School of Tropical Medicine, Liverpool, UK.
Cochrane Database Syst Rev. 2012 Jul 11(7):CD000371. doi: 10.1002/14651858.CD000371.pub4.
The World Health Organization (WHO) recommends treating all school children at regular intervals with deworming drugs in areas where helminth infection is common. The WHO state this will improve nutritional status, haemoglobin, and cognition and thus will improve health, intellect, and school attendance. Consequently, it is claimed that school performance will improve, child mortality will decline, and economic productivity will increase. Given the important health and societal benefits attributed to this intervention, we sought to determine whether they are based on reliable evidence.
To summarize the effects of giving deworming drugs to children to treat soil-transmitted intestinal worms (nematode geohelminths) on weight, haemoglobin, and cognition; and the evidence of impact on physical well being, school attendance, school performance, and mortality.
In February 2012, we searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, EMBASE, LILACS, mRCT, and reference lists, and registers of ongoing and completed trials.
We selected randomized controlled trials (RCTs) and quasi-RCTs comparing deworming drugs for geohelminth worms with placebo or no treatment in children aged 16 years or less, reporting on weight, haemoglobin, and formal test of intellectual development. In cluster-RCTs treating communities or schools, we also sought data on school attendance, school performance, and mortality. We included trials that included health education with deworming.
At least two authors independently assessed the trials, evaluated risk of bias, and extracted data. Continuous data were analysed using the mean difference (MD) with 95% confidence intervals (CI). Where data were missing, we contacted trial authors. We used GRADE to assess evidence quality, and this is reflected in the wording we used: high quality ("deworming improves...."); moderate quality ("deworming probably improves..."); low quality ("deworming may improve...."); and very low quality ("we don't know if deworming improves....").
We identified 42 trials, including eight cluster trials, that met the inclusion criteria. Excluding one trial where data are awaited, the 41 trials include 65,168 participants.For programmes that treat only children detected as infected (by screening), a single dose of deworming drugs probably increased weight (0.58 kg, 95% CI 0.40 to 0.76, three trials, 139 participants; moderate quality evidence) and may have increased haemoglobin (0.37 g/dL, 95% CI 0.1 to 0.64, two trials, 108 participants; low quality evidence), but we do not know if there is an effect on cognitive functioning (two trials, very low quality evidence).For a single dose of deworming drugs given to all children in endemic areas, there were mixed effects on weight, with no effects evident in seven trials, but large effects in two. Overall our analysis indicated that we are uncertain whether there was an effect on weight (nine trials, 3058 participants; very low quality evidence). For haemoglobin, deworming made little or no difference (0.02 g/dL, 95% CI -0.05 to 0.09, four trials, 1992 participants; low quality evidence), and we don't know if it improves cognition (one trial, very low quality evidence).For multiple doses of deworming drugs with follow up for up to one year given to all children in endemic areas, we are uncertain if there is an effect on weight (0.06 kg, 95% CI -0.17 to 0.30; seven trials, 2460 participants; very low quality evidence); cognition (three trials, very low quality evidence); or school attendance (4% higher attendance; 95% CI -6 to 14; two trials, 75 clusters and 143 individually randomized participants, very low quality evidence). For haemoglobin, the intervention may have little or no effect (mean 0.01 g/dL lower; 95% CI 0.14 lower to 0.13 higher; four trials, 807 participants; low quality evidence).For multiple doses of deworming drugs with follow up beyond one year given to all children in endemic areas there were five trials with weight measures. One cluster-RCT of 3712 children in a low prevalence area showed a large effect (average gain of 0.98kg), whilst the other four trials did not show an effect, including a cluster-RCT of 27,995 children in a moderate prevalence area. Overall, we are uncertain if there is an effect for weight (five trials, 302 clusters and 1045 individually randomized participants; very low quality evidence). For other outcomes, we are uncertain whether deworming affects height (-0.26 cm; 95%CI -0.84 to 0.31, three trials, 1219 participants); haemoglobin (0.02 g/dL, 95%CI 0.3 to 0.27, two trials, 1365 participants); cognition (two trials), or school attendance (mean attendance 5% higher, 95% CI -0.5 to 10.5, one trial, 50 clusters).Stratified analysis to seek subgroup effects into low, medium and high helminth endemicity areas did not demonstrate any pattern of effect. We did not detect any significant effects for any primary outcomes in a sensitivity analysis only including trials with adequate allocation concealment.One million children were randomized in a deworming trial from India with mortality as the primary outcome. This was completed in 2005 but the authors have not published the results.
AUTHORS' CONCLUSIONS: Screening children for intestinal helminths and then treating infected children appears promising, but the evidence base is small. Routine deworming drugs given to school children has been more extensively investigated, and has not shown benefit on weight in most studies, except for substantial weight changes in three trials conducted 15 years ago or more. Two of these trials were carried out in the same high prevalence setting. For haemoglobin, community deworming seems to have little or no effect, and the evidence in relation to cognition, school attendance, and school performance is generally poor, with no obvious or consistent effect. Our interpretation of this data is that it is probably misleading to justify contemporary deworming programmes based on evidence of consistent benefit on nutrition, haemoglobin, school attendance or school performance as there is simply insufficient reliable information to know whether this is so.
世界卫生组织(WHO)建议,在蠕虫感染常见的地区,定期对所有学龄儿童使用驱虫药物进行治疗。WHO表示,这将改善营养状况、血红蛋白水平和认知能力,从而改善健康、智力和上学出勤率。因此,据称学校表现将得到改善,儿童死亡率将下降,经济生产力将提高。鉴于这一干预措施具有重要的健康和社会效益,我们试图确定这些效益是否有可靠的证据支持。
总结给儿童服用驱虫药物治疗土壤传播的肠道蠕虫(线虫类土源性蠕虫)对体重、血红蛋白和认知能力的影响;以及对身体健康、上学出勤率、学校表现和死亡率影响的证据。
2012年2月,我们检索了Cochrane传染病组专业注册库、MEDLINE、EMBASE、LILACS、mRCT以及参考文献列表,以及正在进行和已完成试验的注册库。
我们选择了随机对照试验(RCT)和半随机对照试验,比较16岁及以下儿童使用驱虫药物治疗土源性蠕虫与使用安慰剂或不治疗的效果,报告体重、血红蛋白和智力发育的正式测试结果。在针对社区或学校的整群随机对照试验中,我们还收集了关于上学出勤率、学校表现和死亡率的数据。我们纳入了包括健康教育和驱虫的试验。
至少两名作者独立评估试验、评估偏倚风险并提取数据。连续数据采用均值差(MD)和95%置信区间(CI)进行分析。数据缺失时,我们与试验作者联系。我们使用GRADE评估证据质量,这反映在我们使用的措辞中:高质量(“驱虫可改善……”);中等质量(“驱虫可能改善……”);低质量(“驱虫可能改善……”);极低质量(“我们不知道驱虫是否能改善……”)。
我们确定了42项符合纳入标准的试验,包括8项整群试验。排除一项等待数据的试验后,41项试验包括65168名参与者。对于仅治疗检测出感染的儿童(通过筛查)的项目,单剂量驱虫药物可能增加体重(0.58kg,95%CI 0.40至0.76,三项试验,139名参与者;中等质量证据),可能增加血红蛋白(0.37g/dL,95%CI 0.1至0.64,两项试验,108名参与者;低质量证据),但我们不知道对认知功能是否有影响(两项试验,极低质量证据)。对于在流行地区给所有儿童单剂量服用驱虫药物,对体重的影响不一,七项试验中无明显影响,但两项试验中有显著影响。总体而言,我们的分析表明,我们不确定对体重是否有影响(九项试验,3058名参与者;极低质量证据)。对于血红蛋白,驱虫几乎没有影响(0.02g/dL,95%CI -0.05至0.09,四项试验,1992名参与者;低质量证据),我们不知道是否能改善认知(一项试验,极低质量证据)。对于在流行地区给所有儿童多次服用驱虫药物并随访长达一年,我们不确定对体重(0.06kg,95%CI -0.17至0.30;七项试验,2460名参与者;极低质量证据)、认知(三项试验,极低质量证据)或上学出勤率(出勤率提高4%;95%CI -6至14;两项试验,75个群组和143名单独随机分组的参与者,极低质量证据)是否有影响。对于血红蛋白,干预可能几乎没有影响(平均降低0.01g/dL;95%CI降低0.14至升高0.13;四项试验,807名参与者;低质量证据)。对于在流行地区给所有儿童多次服用驱虫药物并随访超过一年,有五项试验测量了体重。一项在低流行地区对3712名儿童进行的整群随机对照试验显示有显著影响(平均增加0.98kg),而其他四项试验未显示有影响,包括一项在中等流行地区对27995名儿童进行的整群随机对照试验。总体而言,我们不确定对体重是否有影响(五项试验,302个群组和1045名单独随机分组的参与者;极低质量证据)。对于其他结果,我们不确定驱虫是否影响身高(-0.26cm;95%CI -0.84至0.31,三项试验,1219名参与者)、血红蛋白(0.02g/dL,95%CI 0.3至0.27,两项试验,1365名参与者)、认知(两项试验)或上学出勤率(平均出勤率提高5%,95%CI -0.5至10.5,一项试验,50个群组)。按低、中、高蠕虫流行地区进行亚组效应分层分析未显示出任何效应模式。在仅包括分配隐藏充分的试验的敏感性分析中,我们未检测到任何主要结果有显著影响。在印度进行的一项以死亡率为主要结果的驱虫试验中,有100万儿童被随机分组。该试验于2005年完成,但作者尚未发表结果。
筛查儿童肠道蠕虫并治疗感染儿童似乎有前景,但证据基础薄弱。对学龄儿童常规使用驱虫药物的研究更为广泛,大多数研究未显示对体重有益,除了15年前或更早进行的三项试验中有显著的体重变化。其中两项试验是在相同的高流行环境中进行的。对于血红蛋白,社区驱虫似乎几乎没有影响,关于认知、上学出勤率和学校表现的证据总体较差,没有明显或一致的影响。我们对这些数据的解释是,基于营养、血红蛋白、上学出勤率或学校表现持续受益的证据来证明当代驱虫计划可能具有误导性,因为根本没有足够可靠的信息来确定是否如此。